PACGET

Paclitaxel is among the most versatile chemotherapeutic drug used for the treatment of cancer.

Paclitaxel is among the most versatile chemotherapeutic drug used for the treatment of cancer. It was arguably the most important discovery in cancer treatment when it was launched worldwide as ‘Taxol’ in mid-90s. Today, paclitaxel is the backbone of several chemotherapy regimens used for ovarian cancer, breast cancer and lung cancer besides many other malignant tumours. Standard pretreatment regimen with dexamethasone 10 mg (for doses < 100 mg/m2) and 20 mg (for doses > 100 mg/m2) I.V. (see Decmax) along with diphenhydramine 50 mg I.V. and an H2-receptor antagonist I.V. should be administered 30-60 minutes before treatment.

Indications:

  • As first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy in combination with cisplatin
  • For the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy
  • For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • In combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy
  • For the second-line treatment of AIDS-related Kaposi’s sarcoma
Generic Name Strength Standard Type Packing Pack Size
Paclitaxel 30 mg USP INJ Vial 5 ml
Paclitaxel 100 mg USP INJ Vial 17 ml
Paclitaxel 260mg USP INJ Vial 43.5 ml
Paclitaxel 300mg USP INJ Vial 1 Vial